
Testosterone Cypionate and Blood Pressure: The 2025 Warning
Testosterone cypionate and blood pressure became a labeling issue in February 2025, when the FDA required every testosterone product to carry a blood pressure warning after a series of 24-hour monitoring studies "confirmed an increase in blood pressure with use of all testosterone products." The Depo-Testosterone label now says it plainly: testosterone can raise blood pressure, and higher blood pressure raises cardiovascular risk over time.
This article sets out how large the rise is, product by product, what the TRAVERSE cardiovascular outcomes trial found, why injections raise hematocrit more than gels and what that means, and how a man on cypionate monitors it. Sources: the FDA class-wide labeling notice (February 28, 2025), the Depo-Testosterone, Xyosted, Jatenzo, Tlando and Kyzatrex labels (2025 to 2026), ambulatory blood pressure studies published 2021 to 2025, the TRAVERSE trial (2023), a 2026 review in the Journal of the American Heart Association, and studies of hematocrit and cardiovascular events.
What the Label Says Now
From the Depo-Testosterone label, revised October 2025:
"Testosterone can increase blood pressure which can increase cardiovascular (CV) risk over time."
- 1Blood pressure should be monitored periodically, especially in men with hypertension.
- 2Testosterone is not recommended in men with uncontrolled hypertension.
- 3Hemoglobin and hematocrit should be checked periodically.
The 2025 class-wide change
Recommended for all labels
TRAVERSE trial results; a blood pressure warning where there was none
Added so far
TRAVERSE in the Xyosted, Jatenzo, Tlando and Kyzatrex labels; not yet in Depo-Testosterone
Removed
Boxed warning language on increased risk of adverse cardiovascular outcomes
Kept
The limitation of use for age-related low testosterone (HHS requested its removal in June 2026)
Several oral and subcutaneous products had carried boxed warnings specifically about blood pressure; those were moved into the warnings section during 2025. Depo-Testosterone never had a boxed warning, so its change was the new paragraph. The rest of the label is summarized on the Depo-Testosterone page.
How Much Blood Pressure Rises
Average 24-hour systolic change on testosterone, ambulatory monitoring studies
Jatenzo, oral undecanoate
+4.9 / +2.5 mm Hg at 4 months; had not plateaued
Label, 2025
Tlando, oral undecanoate
+4.3 / +1.4 mm Hg at about 16 weeks
Label, 2026
Xyosted, subcutaneous enanthate
+3.9 / +1.5 mm Hg at 12 weeks
Label, 2025
Transdermal system
+3.5 mm Hg at 16 weeks
Endocrine Practice, 2024
Testosterone gel 1.62%
+1.9 mm Hg at 16 weeks
Andrology, 2025
Kyzatrex, oral undecanoate
+1.7 mm Hg at 4 months
Label, 2026
Three details matter more than the averages:
- 1For the oral products the rise was larger in men already treated for hypertension: +5.4 mm Hg systolic on Jatenzo and +3.4 on Kyzatrex in that subgroup. The subcutaneous enanthate figure did not differ between the two groups.
- 2In the one-year Xyosted study, 10% of men started or changed blood pressure medication, and hypertension was reported as an adverse event in 12.7%.
- 3A 2026 review concluded that the size of the rise "differs by individual product rather than by route", so the subcutaneous enanthate number is not a stand-in for cypionate. No ambulatory study of cypionate itself has been published.

TRAVERSE: What the Outcomes Trial Found
TRAVERSE enrolled 5,246 men aged 45 to 80 with low testosterone and existing cardiovascular disease or high risk, and gave them 1.62% testosterone gel or placebo.
TRAVERSE results, testosterone vs placebo
Major adverse cardiac events
7.0%
7.3%
Atrial fibrillation
3.5%
2.4%
Arrhythmia needing intervention
5.2%
3.3%
Acute kidney injury
2.3%
1.5%
Pulmonary embolism
0.9%
0.5%
Systolic pressure in TRAVERSE rose by 1.0 mm Hg on testosterone against a fall of 0.5 on placebo at 36 months. The trial met its non-inferiority test for heart attack, stroke and cardiovascular death, which is why the boxed cardiovascular language was removed. Two limits apply to a man on cypionate: the trial used a gel, not an injection, and 61% of participants stopped treatment early. A 2025 meta-analysis of 23 trials with 9,280 men found the same shape: more arrhythmias on testosterone (risk ratio 1.53), no difference in death, stroke or heart attack. The trial is also summarized on the side effects page.
Hematocrit, the Injection-Specific Issue
Testosterone stimulates red blood cell production, and thicker blood raises the workload on the heart and the risk of clots.
Hematocrit and events
Hematocrit above 50% in 66.7% of men on injections, 35.1% on pellets, 12.8% on gels (the injection group was younger with a higher baseline)
Retrospective comparison, Sexual Medicine, 2015
Hematocrit of 52% or more: 5.15% had a cardiovascular event or clot in year 1 vs 3.87% (odds ratio 1.35)
Large database study, Journal of Urology, 2022
Injections produce higher peaks than gels, and the peaks drive red cell production, which is one reason the hematocrit numbers differ so much between routes. Weekly or twice-weekly dosing of the same total, which narrows the peaks, is the adjustment most prescribers make first; the curves behind that are on the half-life page. A direct link from hematocrit to measured blood pressure has not been established in these studies.
Monitoring on Cypionate
- 1A baseline blood pressure, ideally an average of home readings, before the first injection.
- 2A recheck at each visit in the first months, and at home if baseline was high-normal or treated.
- 3Hematocrit at baseline and at 3 to 6 months, then periodically; the oral undecanoate label checks it every 3 months.
- 4Uncontrolled hypertension treated before starting, since the labels advise against testosterone in that case.
- 5A rise in pressure or hematocrit prompts a dose or interval change before anything else.
The full monitoring schedule, with the hematocrit thresholds at which guidelines advise reducing or stopping, is in the TRT guide.

Frequently Asked Questions
The label says testosterone can increase blood pressure. Every product studied with 24-hour monitoring raised average systolic pressure by about 2 to 5 mm Hg; no such study has been published for cypionate specifically.
The labels advise against testosterone in uncontrolled hypertension and recommend monitoring in men with treated hypertension, in whom the rise was larger in the studies. The decision is a prescriber's.
In February 2025 the FDA removed boxed language on increased cardiovascular outcome risk after TRAVERSE showed no increase in major cardiac events, and added a blood pressure warning to every testosterone product.
Major adverse cardiac events in 7.0% on testosterone gel vs 7.3% on placebo; more atrial fibrillation, acute kidney injury and pulmonary embolism on testosterone.
Injections create higher peaks, which stimulate red cell production more. In one comparison, 66.7% of men on injections had a hematocrit above 50% against 12.8% on gels.
The labels say periodically; in practice at each visit in the first months and at home for men with high-normal or treated pressure.
Cypionat.com is an independent educational resource. We are not affiliated with Pfizer, Azurity, Antares or any manufacturer, pharmacy or clinic. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.
Editorial
Author
Comments (0)
Be the first to comment on this article.


